Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Cancer Discov. 2022 Mar 1;12(3):604-605. doi: 10.1158/2159-8290.CD-21-1643.
Isocitrate dehydrogenase 1 mutations (mIDH1) are common in cholangiocarcinoma, but their exact mechanisms in cholangiocarcinoma initiation and maintenance are unclear. In this issue of Cancer Discovery, Wu and colleagues identify immune suppression via TET2 inactivation as the primary means by which mIDH1 maintains cholangiocarcinoma survival, leading to an efficacious new combination of mIDH1 inhibitors and immune checkpoint blockade targeting regulatory T cells. See related article by Wu et al., p. 812 (9).
异柠檬酸脱氢酶 1 突变（mIDH1）在胆管癌中很常见，但它们在胆管癌发生和维持中的确切机制尚不清楚。在本期《Cancer Discovery》中，Wu 及其同事发现 TET2 失活引起的免疫抑制是 mIDH1 维持胆管癌细胞存活的主要方式，这为 mIDH1 抑制剂与针对调节性 T 细胞的免疫检查点阻断的联合治疗提供了新的思路。Wu 等人的相关研究见第 812 页（9）。
